Production of self-assembling biomaterials for tissue engineering.
Self-assembling peptide-based biomaterials are being developed for use as 3D tissue engineering scaffolds and for therapeutic drug-release applications. Chemical synthesis provides custom-made peptides in small quantities, but production approaches based upon transgenic organisms might be more cost-effective for large-scale peptide production. Long lead times for developing appropriate animal clones or plant lines and potential negative public opinion are obstacles to these routes. Microbes, particularly safe organisms used in the food industry, offer a more rapid route to the large-scale production of recombinant self-assembling biomaterials. In this review, recent advances and challenges in the recombinant production of collagen, elastin and de novo designed self-assembling peptides are discussed.
Kyle
Stuart
S
Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK. bmbsky@leeds.ac.uk
Aggeli
Amalia
A
Ingham
Eileen
E
McPherson
Michael J
MJ
D000818:Animals; D001419:Bacteria / Q000378:metabolism; D001672:Biocompatible Materials / Q000378:metabolism*; D004337:Drug Carriers / Q000494:pharmacology*; D005658:Fungi / Q000378:metabolism; D030781:Organisms, Genetically Modified / Q000378:metabolism; D010944:Plants; D023822:Tissue Engineering / Q000379:methods*
D001672:Biocompatible Materials; D004337:Drug Carriers